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Abstract Chlamydia trachomatis infection is the most
prevalent bacterial sexually transmitted infection and may
influence pregnancy outcome. This study was conducted to
assess the effect of chlamydial infection during pregnancy
on premature delivery and birthweight. Pregnant women
attending a participating midwifery practice or antenatal
clinic between February 2003 and January 2005 were eligi-
ble for the study. From 4,055 women self-administered
questionnaires and urine samples, tested by PCR, were
analysed for C. trachomatis infection. Pregnancy outcomes
were obtained from midwives and hospital registries. Ges-
tational ages and birthweights were analysed for 3,913
newborns. The C. trachomatis prevalence was 3.9%, but
varied by age and socio-economic background. Chlamydial
infection was, after adjustment for potential confounders,
associated with preterm delivery before 32 weeks (OR 4.35
[95% CI 1.3, 15.2]) and 35 weeks gestation (OR 2.66 [95%
CI 1.1, 6.5]), but not with low birthweight. Of all deliveries
before 32 weeks and 35 weeks gestation 14.9% [95% CI 4.5,
39.5] and 7.4% [95% CI 2.5, 20.1] was attributable to
C. trachomatis infection. Chlamydia trachomatis infection
contributes significantly to early premature delivery and
should be considered a public health problem, especially in
young women and others at increased risk of C. trachomatis
infection.
Keywords Chlamydia trachomatis  Pregnancy 
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Introduction
Chlamydia trachomatis is an important cause of sexually
transmitted infections (STIs) in women, which may lead to
pelvic inflammatory disease, tubal infertility, ectopic
pregnancy, and chronic abdominal pain [1–4]. Chlamydial
infection during pregnancy may in addition influence
pregnancy outcomes leading to premature rupture of
membranes, prematurity, low birthweight and perinatal
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mortality, and cause neonatal conjunctival and respiratory
infection [5–7]. The literature regarding the detrimental
effects of C. trachomatis infection on pregnancy outcome,
however, yields conflicting results that seem primarily due
to differences in study design, population and microbio-
logical tests employed [8–24].
Screening for C. trachomatis in pregnant women has
revealed prevalence rates varying from 0 to 37% and var-
ious associated risk factors for infection including in par-
ticular age and socio-economic status [25–27].
In the Netherlands, a chlamydial prevalence of 2.5%
was reported in women [28]. However, prenatal screening
for C. trachomatis is not routine obstetrical practice in the
Netherlands and data on pregnant women and pregnancy
outcome are lacking.
The objective of this study was to assess the prevalence
of C. trachomatis infection in pregnant women and to
investigate the association of chlamydial infection with the
risks of preterm delivery and low birthweight or being
small for gestational age.
Methods
Design
This Chlamydia trachomatis study was embedded in the
Generation R Study, which is a population-based, non-
interventional, prospective cohort study designed to identify
early environmental and genetic determinants of growth,
development and health of children, starting from foetal life
until adolescence [29, 30]. Pregnant women, attending one
of the participating midwifery practices or antenatal clinics
and expected to deliver in Rotterdam, were eligible for the
study. Regular health care workers (midwives, obstetricians)
informed the women about the study. Most women spoke
Dutch, otherwise the study was explained and question-
naires were provided in their native language. Enrolment
was scheduled in early pregnancy (gestational age \ 18 -
weeks) at the first routine foetal ultrasound examination, but
was allowed until delivery. Women scheduled for termina-
tion of pregnancy and women with a miscarriage or perinatal
death prior to or at the first ultrasound were not included.
Generation R started in 2002; the Chlamydia sub-study was
between February 2003 and January 2005.
Risk factors
Data were obtained using confidentially administered stan-
dardized questionnaires at the time of inclusion. Unan-
swered questions were registered as missing data. Maternal
age was defined as age at enrolment. Ethnicity was defined
according to the classification of Statistics Netherlands [30].
Most women were Dutch (49%), Surinamese (9%), Turkish
(9%) or Moroccan (7%). Educational levels of participating
women were defined in groups by highest attained education
(primary school, secondary school, higher education).
Marital status was defined as married if married or living
together in partnership. Further information was obtained
regarding gravidity, number of sexual partners in the year
prior to pregnancy, history of an STI, and use of cigarettes,
alcohol and drugs.
Microbiological diagnosis
Women provided a first-void urine specimen to test for C.
trachomatis at enrolment. Urines were stored at 4C,
transported the same or following working day, and pro-
cessed within 24 h of receipt by the laboratory. DNA was
isolated from pooled urine specimens using the MagNA
Pure LC Bacterial DNA isolation Kit III (Roche Molecular
Systems, Alameda, USA) and amplified by polymerase
chain reaction (PCR) (Cobas Amplicor, Roche Molecular
Diagnostics, Branchburg, USA) [31]. In brief, pools were
made of five individual urines by adding 200 ll of each
urine into one tube. From each pool the full 1,000 ll were
taken, and centrifuged for 10 min. Subsequently, 900 ll
were removed and the pellet was resuspended in 100 ll of
the remaining supernatant, mixed with 130 ll lysis buffer
and 20 ll proteinase K, incubated for 10 min, and there-
after denatured for 10 min. Finally, DNA was isolated in
the automated MagNA Pure LC using a sample volume of
250 ll and an elution volume of 100 ll. Then, 25 ll was
used for PCR. Urines from positive pools were individually
re-tested and reported as negative or positive.
Pregnancy outcomes
Information about pregnancy outcomes (miscarriage, peri-
natal death, gestational age, birthweight) was obtained post-
natally from midwives and hospital registries. Gestational age
was established by foetal ultrasound examination instead of
last menstrual period. Establishing gestational age by using
the first day of the last menstrual period is not reliable for a
variety of reasons including the large number of women who
do not know their exact date, have irregular menses or am-
enorrhoea, use oral contraceptives or bleed in early preg-
nancy. Establishing gestational age by foetal ultrasound can
overcome these problems. Foetal ultrasound was performed
by regular health care providers at each prenatal visit, which
were planned in early pregnancy (gestational age \ 18 -
weeks), mid-pregnancy (gestational age 18–25 weeks) and
late pregnancy (gestational age C 25 weeks). The individual
time scheme of assessments depended on the specific gesta-
tional age at enrolment. Pregnancy dating-curves were
derived in a subsample of the Generation R study cohort
including subjects with complete data on both the first day of
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the last menstrual period and crown-rump length or biparietal
diameter. Subsequently, gestational age at prenatal enrolment
and, as a consequence, at delivery was retrospectively
established by crown-rump length or biparietal diameter
measured in early pregnancy or mid-pregnancy (30). Preterm
birth was defined as delivery at a gestational age of less than
37 weeks, with subgroups of gestational ages less than
32 weeks and less than 35 weeks. Low birthweight was
defined as weight below 2,500 g, small for gestational age
(SGA) as birthweight less than 2 standard deviation scores
(SDSs) below the mean for gestation. Birthweight measure-
ments were converted into gestational age adjusted SDS [32].
Ethical aspects
The C. trachomatis study was embedded within the
framework of Generation R [29, 30], which were both
approved by the Medical Ethical Committee for Research
on Human Subjects of the Erasmus MC, Rotterdam.
Written informed consent was obtained from all partici-
pants. Generation R provided data anonymously.
Data analysis
Associations of C. trachomatis infection during pregnancy
with socio-economic and life style risk factors of women
were assessed using multiple logistic regression models.
Unequivocal confounders were selected based on previous
studies. Associations for each risk factor were studied while
adjusting for all other risk factors and the confounders
alcohol, drugs and smoking. We imputated missing data in
other risk factors and confounders with multiple imputa-
tions. Preterm birth was analysed using multiple logistic
regression models. We adjusted for maternal age, ethnicity,
gravidity, education, and smoking).
The Kaplan–Meier procedure was used to illustrate the
proportion of women delivering at given gestational ages
and the Breslow test to calculate the significance of the
difference between gestational ages at delivery of chla-
mydia-positive and chlamydia-negative women.
The proportion of preterm delivery attributable to C. tra-
chomatis in women in the total population was assessed
using the population attributable fraction of risk (PAR) [33].
The PAR was calculated with the observed relative risk (RR)
and the population fraction with chlamydial infection (PF):
PAR ¼ RR  1ð ÞPF½ = 1 þ RR  1ð ÞPF½  :
Birthweight as a continuous variable was analysed using
multiple linear regression models; low birthweight and
SGA with multiple logistic regression models. The latter
were adjusted for known determinants of low birthweight
(maternal age, ethnicity, gravidity), socio-economic status
and life style related variables (education, smoking).
Measures of association are presented with 95% confi-
dence intervals (CI).
Statistical analysis was performed using the Statistical
Package of Social Sciences version 11.0 for Windows
(SPSS Inc, Chicago, IL, USA). Data imputation was done
with the MI procedure in SAS 9.13.
Results
Population for analysis
During the study period Generation R enrolled 5,167
pregnant women (Fig. 1), of whom 4,676 women (90%)
provided a urine sample and were enrolled in the Chla-
mydia sub-study. Of these, 621 urines could not be mat-
ched to the respective questionnaires in the database. Urine
samples and data from 4,055 women were analysed for the
prevalence and risk factors for C. trachomatis infection.
Half the women were included within the first 14 weeks of
their pregnancy, 95% within 22 weeks.
Enrolment in Generation R Study  
(n=5,167 women)
February 2003-January 2005 
Excluded (n=621): 
urine samples not matching to questionnaires  
n=4,055 
Data on C. trachomatis infection and questionnaire for 
analysis of prevalence and risk factors 
Excluded (n=142): 
twin pregnancies (n=34) 
loss to follow-up (n=28)  
miscarriage (n=11)  
perinatal death (n=51) 
missing gestational age or birthweight (n=18) 
n=3,913
Data on C. trachomatis infection, 
gestational age and birthweight for analysis of 
prematurity, low birthweight and SGA
Enrolment in C. trachomatis study 
(n=4,676 women)
February 2003-January 2005
Not enrolled in C. trachomatis study (n=491): 
urine samples not available 
Fig. 1 Profile of the generation R sub-study on Chlamydia
trachomatis
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Prevalence
Chlamydia trachomatis was detected in 157 of 4,055
(3.9%) women. Age-specific prevalences were 13.5% in
women age B 20 years, 6.7% between 21 and 25 years,
3.3% between 26 and 30 years and 1.6% in women over
30 years. Prevalences were highest in Antillean (16.2%),
Cape Verdean (10.8%) or Surinamese (9.1%) women, and
women with low education (5.8%), single marital status
(11.9%), first pregnancies (4.5%), multiple sexual partners
(7.7%), or a history of an STI (6.3%) (Table 1).
Women with missing data on ethnicity, education and
smoking had higher chlamydia rates than women with data
recorded: 6.5% versus 3.6% (P = 0.01), 6.3% versus 3.6%
(P = 0.01) and 4.8% versus 3.4% (P = 0.04), respec-
tively. Women with missing data on other variables had not
higher rates of chlamydial infection.
Risk factors
In the unadjusted analysis age below 30 years, Antillean, Cape
Verdean and Surinamese ethnicity, education, single marital
status, multiple sexual partners and history of an STI were
significantly associated with chlamydial infection (Table 1).
In the adjusted analysis age below 21 years, Antillean eth-
nicity and single marital status remained risk factors for
infection; other maternal factors were not independently
associated. Moroccan or Turkish women had a lower risk.
Table 1 Socio-economic and life style risk factors of Chlamydia trachomatis infection in pregnant women
Chlamydia trachomatis infection
Risk factors Negative Positive Crude Adjusted
n = 3,898 n = 157 (%) OR (95% CI) OR (95% CI)#
Age groups (n = 4055)
\ 21 217 34 (13.5) 9.43 (5.6–15.8)** 1.79 (1.2–2.6)**
21–25 741 53 (6.7) 4.31 (2.7–6.8)** 1.29 (1.0–1.7)
26–30 1194 41 (3.3) 2.07 (1.3–3.4)** 0.89 (0.7, 1.2)
[ 30 1746 29 (1.7) 1.00 1.00
Ethnicity (n = 3730)
Dutch 1748 33 (1.8) 1.00 1.00
Cape Verdean 149 18 (10.8) 6.40 (3.5–11.6)** 1.54 (0.9–2.5)
Antillean 109 21 (16.2) 10.21 (5.7–18.2)** 2.27 (1.4–3.7)**
Surinamese 310 31 (9.1) 5.30 (3.2–8.8)** 1.43 (1.0–2.1)
Moroccan/Turkish 610 14 (2.2) 1.22 (0.7–2.3) 0.51 (0.3–0.9)*
Other (non-) western 668 19 (2.8) 1.51 (0.9–2.7) 0.68 (0.4–1.1)
Education (n = 3656)
Primary school 389 24 (5.8) 3.32 (1.9–5.8)** 1.28 (0.9–1.8)
Secondary school 1573 79 (4.8) 2.71 (1.8–4.2)** 0.93 (0.7–1.2)
Higher education 1,562 29 (1.8) 1.00 1.00
Marital status (n = 3648)
Not married 479 65 (11.9) 5.88 (4.1–8.4)** 1.60 (1.3–2.0)**
Married 3,034 70 (2.3) 1.00 1.00
Gravidity [ 1 (n = 4011)
No 1,719 81 (4.5) 1.00 1.00
Yes 2,138 73 (3.3) 0.72 (0.5–1.0) 0.85 (0.7–1.0)
Multiple sexual partners in year prior to pregnancy (n = 3289)
No 2,918 99 (3.3) 1.00 1.00
Yes 251 21 (7.7) 2.47 (1.5–4.0)** 1.23 (0.7–2.2)
History of STI (n = 3313)
No 2,778 100 (3.5) 1.00 1.00
Yes 370 25 (6.3) 1.88 (1.2–3.0)** 1.35 (0.7–2.5)
Do not know 38 2 (5.0) 1.46 (0.4–6.2) 0.79 (0.3–2.2)
Values are frequencies and odds ratios (95% CI), * P-value \ 0.05, ** P-value \ 0.01
# Adjusted for all other risk factors, use of drugs, alcohol and smoking with multiple imputation of missing data in the other factors
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Pregnancy outcomes
Pregnancy outcomes are shown in Table 2. Of 4,055
pregnancies 3,931 resulted in live singleton births and 34
in live twins. Women who gave birth to twins were more
often chlamydia-positive than women who had singletons
(P = 0.05). Miscarriage (n = 11) and perinatal death (33
stillbirth, 18 neonatal death) occurred in 1.5% pregnan-
cies. These adverse events were not associated with
chlamydial infection during pregnancy. Preterm delivery
occurred in 190 women (4.9%) of which prematurity
before 32 weeks (0.6%) and 35 weeks (1.6%) of gestation
was significantly associated with chlamydial infection
(Table 2). No significant association was observed with
low birthweight.
After exclusion of women who were lost to follow up, or
who had twin pregnancies, a miscarriage or perinatal death,
the effect of Chlamydia on gestational age and birthweight
was further analysed for 3,913 women and neonates.
Gestational age
The distribution of gestational ages according to the
maternal chlamydial status is shown in a Kaplan–Meier
plot (Fig. 2). Chlamydia-positive women had a signifi-
cantly shorter duration of gestation (P Breslow = 0.02).
Unadjusted analysis (Table 3) showed that chlamydia-
positive women had a significantly higher risk of preterm
delivery before 32 weeks compared to delivery at term
(OR 5.69 [95% CI 1.90, 17.03]). After adjustment for
maternal age, ethnicity, education, gravidity, and smoking
Table 2 Pregnancy outcomes of women and their association with Chlamydia trachomatis infection
Outcomes Chlamydia trachomatis infection
Negative Positive Percentage positive (95% CI) P-value*
All outcomes (n = 4,055)
All women enrolled 3,898 157 3.9 (3.3–4.5)
Live pregnancy outcomes (n = 4,055)
Live singleton birth 3,780 151 3.8 (3.2–4.4) 1.0 (reference)
Live twin birth 30 4 11.8 (0.3–21.9) 0.05
Lost to follow up 26 2 7.1 (0.0–17.3) 0.29
Adverse pregnancy outcomes
Demise (n = 4,055)
Miscarriage 11 0 0 1.00
Perinatal death 51 0 0 0.27
Gestational age** (n = 3,913)
Term, C 37 weeks 3,583 140 3.8 (3.2–4.4) 1.0 (reference)
Prematurity, \ 37 weeks 180 10 5.3 (2.1–8.5) 0.33
Prematurity, \ 35 weeks 57 7 10.9 (3.1–18.8) 0.01
Prematurity, \ 32 weeks 18 4 18.2 (0.7–36.7) 0.01
Birthweight** (n = 3,913)
C 2,500 g 3,589 140 3.8 (3.1–4.4) 1.0 (reference)
\ 2,500 g 174 10 5.4 (2.1–8.7) 0.25
* P-value (Chi-square or Fishers exact test) for comparison of Chlamydia trachomatis prevalence with respective outcome categories of live
singleton birth, gestational age C 37 weeks, and birthweight C 2,500 gram
** Including live singleton birth outcomes only
26 28 30 32 34 36 38 40 42 44
0.00
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p=0.02
gestational age (weeks)
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Fig. 2 Kaplan-Meier analysis of duration of gestation at delivery in
women with and without Chlamydia trachomatis infection
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a significant four-fold increased risk (OR 4.35 [95% CI
1.3–15.2]) remained. Chlamydia-positive women also had
a significantly higher risk of preterm delivery before
35 weeks (OR 3.14 [95% CI 1.4–7.0]), which also
remained after adjustment for the above-stated confounders
(OR 2.66 [95% CI 1.1–6.5]). Chlamydia-positive women
had no increased risk of preterm delivery before 37 weeks.
The fraction of premature deliveries before 32 and
35 weeks gestation attributable to C. trachomatis infection
in women was 14.9% (95% CI 4.5–39.5) and 7.4% (95%
CI 2.5–20.1), respectively.
Birthweight
Crude analysis of differences in birthweight (in grams)
between neonates born to chlamydia-positive and chla-
mydia-negative women showed a significant difference
(-114 g [95% CI -206, -23]), which disappeared after
adjustment for gestational age, maternal age, ethnicity,
education, gravidity and smoking (-20 g [95% CI -98,
58]). A comparison of low birthweight (n = 184) between
the two groups also showed no significant difference
(unadjusted OR 1.47 [95% CI 0.8–2.8]; adjusted OR 0.95,
[0.4–2.2]). Analysis of the correlation between birthweight,
expressed in SDSs, of neonates and their gestational ages
according to the maternal chlamydial status is demonstrated
in Fig. 3. This figure suggests that neonates born to chla-
mydia-positive women had, on average, a lower birthweight
SDS, especially when prematurely born. However, the dif-
ference did not reach statistical significance; also not after
stratification by gestational ages (Table 4). Furthermore,
neonates born to chlamydia-positive women were not more
often SGA than neonates born to chlamydia-negative
women, 3.3% versus 3.6% (P = 0.88).
Discussion
This study provides evidence that C. trachomatis infection
during pregnancy is associated with preterm delivery, but
not with low birthweight or being small for gestational age.
Young age, Antillean ethnicity and single marital status
were independent risk factors for C. trachomatis infection
in pregnant women.
The strength of this study is its population-based, non-
interventional and prospective design with a large number
of well-described participants, adjustments for many
potential confounders, use of a highly sensitive microbio-
logical test method and near perfect follow-up until
delivery (97%).
A potential weakness is that the Generation R cohort is
slightly skewed towards a relatively affluent, healthy study
population [30]. However, we do not expect this to affect
our results since the study was designed to assess the
effects of Chlamydia on pregnancy outcomes in a non-
hospital based, low-risk population. Another weakness
could be that not all women initially enrolled in the overall
study could be tested for C. trachomatis. We had a non-
response of 9.5% (491 women) for the Chlamydia study.
This may in part be true non-response, but is more likely
due to a change in the Generation R routine with a later
start of inclusion of urine collections for the Chlamydia
study. Another 12.0% (621 women) had to be excluded
because their urines could not be matched to the respective
questionnaires in the database. This was due to logistical
problems in the pilot phase of the Chlamydia study.
However, all risk factors were similarly distributed among
tested and untested women and no differences were found
in median gestational age and mean birthweight
(39.8 weeks versus 39.8 weeks; P = 0.84, 3,408 g versus
3,407 g; P = 0.92). Likewise, no differences were
observed between chlamydia-positive and negative women
regarding the measurement and calculation of gestational
age at the prenatal visits. Furthermore, our numbers were
too small to assess an association of Chlamydia with
miscarriage or perinatal death. Of all enrolled women with
C. trachomatis results, 62 (1.5%) had a miscarriage or
perinatal death. Data on gestational age and birthweight
were not available for these deliveries, but likely is that
Table 3 Risk for preterm delivery among women with Chlamydia trachomatis infection
Risk for preterm delivery
\ 32 weeks \ 35 weeks \ 37 weeks
n = 22 n = 64 n = 190
Unadjusted odds ratio
C. trachomatis infection 5.69 (1.9–17.0)** 3.14 (1.4–7.0)** 1.42 (0.7–2.8)
Adjusted odds ratio#
C. trachomatis infection 4.35 (1.3–15.2)* 2.66 (1.1–6.5)* 1.17 (0.6–2.4)
Analyses are done versus delivery C 37 weeks (n = 3,724)
# Adjusted for maternal age, ethnicity, education, gravidity and smoking with multiple imputation
Values are odds ratios (95% confidence interval), * P-value \ 0.05, ** P-value \ 0.01
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these women delivered relatively more often prematurely.
None of these women tested positive for C. trachomatis.
Theoretically, our effect estimates for associations of
chlamydial infection with gestational age and birthweight
could be biased and exaggerated when these associations
would differ between all fetuses and fetal ‘survivors‘. This
would be the case if C. trachomatis infection would have a
‘protective‘ effect on early fetal death. However, this is
most unlikely [8, 20].
Previous studies of associations between maternal
chlamydial infection and subsequent spontaneous preterm
delivery produced mixed results. Most of these studies
were small compared to our study (less than 1,000 women
included) and were published 10 to over 20 years ago.
Early studies were often based on serology, which does not
reliably distinguish current from past infection [9, 11, 14,
15]. One case–control study found an association between
the presence of IgM anti-chlamydial antibody and preterm
delivery [11]. Studies using cervical culture for C. tra-
chomatis at that time also yielded conflicting results [9, 10,
13, 14]. More recently, sensitive DNA amplification tech-
niques have been used to screen pregnant women for
C. trachomatis, but again with contradicting results
regarding preterm delivery [21–24, 34, 35]. Using this
methodology one case–control study, nested in a USA
study among 2,929 pregnant women, reported a two- to
three-fold increased risk of preterm delivery before
35 weeks gestation [21]. Later, the same group reported
from an observational study among 2,470 women with
bacterial vaginosis or Trichomonas vaginalis infection
enrolled in a multicentre randomized antibiotic treatment
trial that Chlamydia in midterm pregnancy was not asso-
ciated with increased risk of preterm delivery [23]. How-
ever, most of their chlamydia-positive women were treated
between 16–29 weeks gestation. Three more studies in
which chlamydia-positive pregnant women were treated
also found no association with prematurity or a much lower
relative risk for prematurity (1.50) than we found in our
study [24, 34, 35]. In a prospective South-African study
among low-risk pregnant women, chlamydia-positive
24 26 28 30 32 34 36 38 40 42 44
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Fig. 3 Birthweight standard deviation scores (SDS) versus gesta-
tional ages of neonates born to women with and without Chlamydia
trachomatis infection
Table 4 Differences in birthweight between neonates born to women with and without Chlamydia trachomatis infection
Number (%) Mean birth weight SDS Difference in birthweight SDS*
Unadjusted Adjusted#
Gestational age
\ 32 weeks (n = 22)
C. trachomatis - 18 (82) 0.83
C. trachomatis ? 4 (18) -0.72 -1.54 (-3.6–0.5) -1.43 (-4.6–1.7)
\ 35 weeks (n = 64)
C. trachomatis - 57 (89) 0.13
C. trachomatis ? 7 (11) -0.87 -0.99 (-2.2–0.2) -0.79 (-2.2–0.7)
\ 37 weeks (n = 190)
C. trachomatis - 180 (95) -0.26
C. trachomatis ? 10 (5) -0.85 -0.59 (-1.4–0.2) -0.38 (-1.2–0.4)
C 37 weeks (n = 3,723)
C. trachomatis - 3,583 (96) -0.08
C. trachomatis ? 140 (4) -0.19 -0.10 (-0.3–0.1) -0.12 (-0.1–0.3)
SDS standard deviation score
# Adjusted for maternal age, ethnicity, education, gravidity and smoking
Difference and 95% confidence interval calculated with linear regression analysis
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women (cases, n = 40) had a relative risk of 2.20 for
preterm delivery before 37 weeks gestation (controls,
n = 303) [22]. In this study women were also tested for
Syphilis, Gonorrhoea and bacterial vaginosis, which were
found not to be associated with preterm delivery. Likewise,
one of the former studies also found no association
between preterm delivery and syphilis, bacterial vaginosis,
Trichomonas vaginalis and Neisseria gonorrhoeae infec-
tion [35]. The true effect of C. trachomatis on pregnancy
outcomes therefore cannot be fully ascertained from stud-
ies in which pregnant women are screened for Chlamydia
and treated in the first phases of their pregnancy. In con-
trast, our study is prospective, non-interventional and
population-based (n = 4,055), which makes that our find-
ings better estimate the effect of Chlamydia on pregnancy
and are more representative for the population as a whole.
Preterm birth represents a major problem for obstetrics
and neonatology due to its increasing frequency and
accompanying socio-economic impact. We found chla-
mydial infection to be associated with preterm delivery
before 32 and 35 weeks gestation, which was much stronger
for the former indicating that Chlamydia contributes rela-
tively more to early than late prematurity. For such an
important issue, a four-fold increased risk of preterm deliv-
ery before 32 weeks gestation implies that a considerable
proportion (14.9% in our cohort) of preterm deliveries before
32 weeks gestation is attributable to chlamydial infection in
pregnancy. Despite a considerable confidence interval
around the estimate, this would classify C. trachomatis
among the important infective risk factors of early prema-
turity. The attributable fraction remained significant (7.4%)
for preterm delivery before 35 weeks. It should be noted,
however, that the number and proportion of premature
deliveries attributable to Chlamydia highly depends upon the
C. trachomatis prevalence in a given population, and that
some residual confounding as a result of co-infection by
other genitourinary pathogens cannot be excluded. Another
limitation could be that we did not correct for other potential
risk factors as previous preterm delivery, since we did not
have such data, and previous termination of pregnancy in
these women since this potential confounder was only
recently established [36]. Importantly, we had no informa-
tion concerning the use of (macrolide) antibiotics during
pregnancy, but suggest that this would mitigate, rather than
exaggerate, the effect of Chlamydia on pregnancy outcome.
The latter information would have been interesting since
early treatment may prevent preterm birth (34, 35). Finally,
pregnant women are not routinely tested and treated for
Ureaplasma urealyticum or Mycoplasma genitalium in the
Netherlands and neither are women with premature rupture
of the membranes routinely treated with antibiotics.
Extrapolation of our findings to the Netherlands, where
approximately 3,000 neonates are born before 32 weeks
gestation annually [37], showed that C. trachomatis
infection in pregnancy contributes approximately 450 cases
to this burden; for deliveries before 35 weeks gestation
these numbers are 7,100 and 525, respectively. Our finding
of an association between C. trachomatis infection and
premature delivery may be useful in a cost-benefit analysis
of Chlamydia screening during pregnancy.
Interestingly, C. trachomatis infection was more pre-
valent among women who had twins than those who had
singletons, a finding not reported before. Since Chlamydia
is associated with infertility and assisted conception for
infertility is associated with twin pregnancies, an expla-
nation for our findings may be that chlamydia-positive
women were not treated effectively during their infertility
work-up or that they were reinfected. This observation
warrants further study into medical histories of women
with twin deliveries versus women with singletons.
The major risk factors we found are amongst the many
previously described including young age, urban residence,
low socio-economic class, specific ethnic groups, single
marital status and recent changes in sexual partnerships or
sexual promiscuity [9, 26, 38, 39]. Adolescents are at
highest risk of infection, which was also observed in this
study [27]. We could not evaluate urban residence since all
participating women resided in Rotterdam. The risk factors
we found are similar to those reported in another Dutch
community-based study [28, 40]. Importantly, C. tracho-
matis prevalences vary widely [26], which will directly
affect the incidence of complications attributable to this
infection, including preterm delivery.
One may question the design of our study since women
screened and found positive for C. trachomatis were not
treated. The design of our study would face ethical barriers
in countries that have national guidelines or directives
advocating Chlamydia screening and treatment in the
routine of antenatal care, and would be impossible to
perform [41, 42]. However, in most countries of the
European Union, including the Netherlands, screening and
treatment for Chlamydia during pregnancy remains con-
troversial and is currently not recommended in routine
antenatal care [43, 44]. Our study provides novel data that
may well have an impact on the future antenatal screening
strategy in the Netherlands and elsewhere. In addition,
Generation R was designed as a non-interventional follow-
up study [29, 30]. All following substudies, including ours,
had to fit into this overall design. Furthermore, Generation
R provided the data anonymously to protect the privacy of
participants. We, therefore, had no access to names or
addresses of chlamydia-positive women.
In conclusion, C. trachomatis urogenital infection in
pregnant women increases the risk of preterm delivery,
especially early prematurity, such that a significant pro-
portion of preterm deliveries can be attributed to this
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infection. In order to improve birth outcomes, health sys-
tems should consider additional focus on C. trachomatis
infection, especially in young women and others at
increased risk.
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